| News

Artificial Intelligence able to identify potentially life-saving antibiotics

11.01.2022

A computer algorithm has identified antibiotics that that are still effective against infections in which multi-resistant germs are present. University Hospital Basel and the Basel-based Department of Biosystems Science and Engineering at the Swiss Federal Institute of Technology in Zurich will initially put their new method to the test as part of a clinical trial.

Study leader Prof. Adrian Egli with his colleague Aline Cuénod in the laboratory medicine department of the University Hospital Basel (img: USB)

Researchers from University Hospital Basel (USB) and the Department of Biosystems Science and Engineering (D-BSSE) at the Swiss Federal Institute of Technology in Zurich (ETH) in Basel are using innovative computer algorithms in the fight against antibiotic-resistant bacteria. With this new method, the researchers can identify characteristics of antibiotic resistance in germs up to 24 hours earlier. This means that it is clear sooner rather than later which antibiotics can still help patients. The cantons of Basel-Stadt and Basel-Landschaft offered financial support for this research project.

“In cases of severe infection, the time until optimal therapy can be the difference between life and death. A quick and precise diagnosis is extremely important here”, comments Professor Adrian Egli, Head of the Clinical Bacteriology department at USB and study director, in a press release.

Larger clinical study will follow

The study team linked 300,000 mass spectrometry data samples from individual bacteria from four laboratories in north-western Switzerland with the results of antibiotic resistance tests in the laboratory. “Intelligent computer algorithms look for patterns in the data that distinguish bacteria with and without resistance from one another”, explains Caroline Weis, PhD student at the D-BSSE at ETH Zurich in Basel and lead author of the study.

The researchers have published their method in the latest edition of the specialist journal “Nature Medicine”. It must now be confirmed in a larger clinical study carried out as part of everyday hospital operations. Plans are already in place for this to take place at USB.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel startups impress investors
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basel startups impress investors

According to the latest Swiss Venture Capital Report, investments in Swiss startups increased by 44 percent last year. As a...

Read More
Basel Area – exactly the right chemistry for South Korean pharma companies
Basel Area Business & Innovation, Innovation, Invest

Basel Area – exactly the right chemistry for South Korean pharma companies

KPBMA and Basel Area Business & Innovation establish tailored collaboration to support Korean biopharmaceutical companies to enter the European market

Read More
Basel Area supporting three digital health startups
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basel Area supporting three digital health startups

Basel Area Business & Innovation will be offering intensive support to the three winners of its DayOne Digital Health Accelerator...

Read More
Gray establishes presence in Basel
Basel Area Business & Innovation, Innovation, Invest

Gray establishes presence in Basel

The North American fully integrated specialty service provider Gray has established a subsidiary in Basel. The key factors in favor...

Read More
Artificial Intelligence able to identify potentially life-saving antibiotics
Basel Area Business & Innovation, Innovation, Invest

Artificial Intelligence able to identify potentially life-saving antibiotics

A computer algorithm has identified antibiotics that that are still effective against infections in which multi-resistant germs are present. University...

Read More
Investors give Anaveon 110 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Investors give Anaveon 110 million Swiss francs

Anaveon has received investment commitments amounting to 110 million Swiss francs in a Serie B funding round. The Basel-based biopharmaceutical...

Read More
1 2 3 21

Do you have a question? We'd like to hear from you.